Management — NMD Pharma
News — NMD Pharma
Thomas Holm Pedersen - Chief Executive Officer, Associate professor of Physiology and Biophysics in Aarhus, Arhus, Denmark | eMedEvents
Management — NMD Pharma
Thomas Holm Pedersen – CEO – NMD Pharma | LinkedIn
Biotech completes financing round to advance neuromuscular treatments - EPM Magazine
NMD Pharma brænder 41 mio. kr. af sin kæmpeinvestering
NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
NMD Pharma is Strengthening Muscles in Neuromuscular Disorders
NMD Pharma
NMD Pharma raises €38M (~USD 47 Million) SERIES A Financing to Advance Treatments of Neuromuscular Disorders
Management — NMD Pharma
NMD Pharma treats first patient with the firm's most promising drug candidate
Oct 23 | Neuromuscular Drug Development Summit (NMD) | Boston, MA Patch
NMD Pharma - Inkef capital
NMD Pharma A/S | LinkedIn
NMD Pharma is Strengthening Muscles in Neuromuscular Disorders
Rare Neuromuscular Disease Company NMD Pharma Raises USD 3 Million in Seed Financing Round - Lundbeckfonden
NMD Pharma - Inkef capital
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
ALS Therapy Developer NMD Pharma Obtains $47 Million in New Financing
NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
NMD Pharma - PIR International
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
